SPL

0.00%

11.5¢ starpharma holdings limited

FDA meeting, page-3

First 3 Last

Share
Profile

Follow
thrasher

1,737 Posts.

60

22/03/19

10:12

Post #: 37849099
Share

Originally posted by stockrock: ↑

Hi

The CRL would be more detailed than the two words "confirmatory data", but it won't be so prescriptive as to eliminate all ambiguity.

As such, when responding to a CRL there is always an eliminate of guesswork - albeit an educated and informed guess. Hiring ex-FDA consultants is a given when responding to a CRL, each and every pharma company would take this step. It is prudent and expected of Starpharma to do so.

As such, having these consultants don't give me any extra confidence that they will get a favourable outcome with the FDA in this meeting.

Heard of the song "Ironic"? This line springs to mind ... "It's like having 10,000 spoons, when all you need is a knife".

Doesn't matter how many dollars you spend on advice, if the regulatory body wants a knife and you give them 10,000 different types of spoons .. you will still get knocked back.

Something to keep in mind is that the FDA chooses its words very clearly. If they needed more clinical data, they ask for clinical data in their CRL.

If they want another trial, they ask for confirmatory data.

Starpharma are giving them more clinical data (another spoon).

So all I am saying is that Starpharma are going to be fighting an uphill battle at this next FDA meeting. I am not saying they can't win, I am just pointing out that it won't be easy and the odds are currently against them.

Having partial approval for one indication is not ideal, but possible and better than no approved product this year.. but that is pure speculation on our part as we don't know what is in the CRL. It may sound logical, but there are so many possibilities out there ... how do I justify to myself as an investor to place my hard earned cash based on two words "confirmatory data". Especially when I know what that means.

It's risk awareness and capital protection that I am advocating, and my risk appetite is different to everybody else. However I feel an obligation as part of an investor forum and former shareholder to share this view.

Expand

Always respected your views just don’t completely agree with it this time confirmatory data can come from existing data even fda guidelines say this, could be Starpharma also present a plan to provide new data after some adjusted approval. Lots of possible outcomes I just don’t think worst outcome will be the result.

SPL Price at posting: $1.00 Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

DUI

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

HotCopper Highlights: Your most watched stocks for Week 47, 2024

PYC

Scientific conference spotlights PYC's work on blindness disease treatment

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

There are more pages in this discussion • 12 more messages in this thread...

First 3 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 11.5¢		Change 0.000(0.00%)		Mkt cap ! $43.82M

Open	High	Low	Value	Volume
11.0¢	11.5¢	11.0¢	$9.637K	86.93K

Buyers (Bids)

No.	Vol.	Price($)
1	310130	11.0¢

Sellers (Offers)

Price($)	Vol.	No.
11.5¢	264831	4

View Market Depth

No.	Vol.	Price($)
1	6000	0.955
4	25073	0.950
1	3925	0.945
3	8847	0.940
1	10000	0.935

Price($)	Vol.	No.
0.960	4540	2
0.965	15000	1
0.970	13906	2
0.975	10000	1
0.980	19012	1

Last trade - 16.10pm 22/11/2024 (20 minute delay)

SPL (ASX) Chart

FDA meeting, page-3

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

HotCopper Highlights: Your most watched stocks for Week 47, 2024

Scientific conference spotlights PYC's work on blindness disease treatment

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Sales growth pushes Lovisa's fortunes (and shares) upwards

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

FDA meeting, page-3

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

HotCopper Highlights: Your most watched stocks for Week 47, 2024

Scientific conference spotlights PYC's work on blindness disease treatment

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Sales growth pushes Lovisa's fortunes (and shares) upwards

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News